Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.62 - $1.0 $3,116 - $5,026
-5,026 Reduced 98.67%
68 $0
Q3 2023

Nov 14, 2023

SELL
$0.47 - $0.9 $128 - $246
-274 Reduced 5.1%
5,094 $3,000
Q2 2023

Aug 14, 2023

BUY
$0.38 - $1.09 $208 - $597
548 Added 11.37%
5,368 $4,000
Q4 2022

Feb 14, 2023

SELL
$0.54 - $9.8 $161 - $2,930
-299 Reduced 5.84%
4,820 $2,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $12.4 $38 - $3,707
299 Added 6.2%
5,119 $3,000
Q1 2022

May 16, 2022

BUY
$1.78 - $8.5 $5,019 - $23,970
2,820 Added 141.0%
4,820 $18,000
Q4 2021

Feb 14, 2022

BUY
$7.3 - $11.24 $14,600 - $22,480
2,000 New
2,000 $16,000

Others Institutions Holding SABS

About SAB Biotherapeutics, Inc.


  • Ticker SABS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,030,900
  • Market Cap $172M
  • Description
  • SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases ...
More about SABS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.